87018-59-5 Usage
Uses
Used in Pharmaceutical Industry:
(+/-)11-HDOHE is used as a therapeutic agent for its anti-inflammatory and anti-oxidative properties, which can help in the treatment of cardiovascular disease, cancer, and other inflammatory disorders.
Used in Nutraceutical Industry:
(+/-)11-HDOHE is used as a dietary supplement to support overall health and well-being by promoting the regulation of blood pressure, immune function, and lipid metabolism.
Used in Research and Development:
(+/-)11-HDOHE is used as a target for further research to better understand its precise mechanisms of action and physiological effects, which can lead to the development of new therapeutic strategies and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 87018-59-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,0,1 and 8 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 87018-59:
(7*8)+(6*7)+(5*0)+(4*1)+(3*8)+(2*5)+(1*9)=145
145 % 10 = 5
So 87018-59-5 is a valid CAS Registry Number.
87018-59-5Relevant articles and documents
OXYLIPINS FROM LONG CHAIN POLYUNSATURATED FATTY ACIDS AND METHODS OF MAKING AND USING THE SAME
-
Page/Page column 59, (2008/06/13)
Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.